SG Americas Securities LLC Sells 29,070 Shares of InMode Ltd. (NASDAQ:INMD)

SG Americas Securities LLC lessened its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,541 shares of the healthcare company's stock after selling 29,070 shares during the quarter. SG Americas Securities LLC owned 0.05% of InMode worth $744,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Nisa Investment Advisors LLC grew its position in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company's stock valued at $60,000 after purchasing an additional 2,694 shares during the period. Quarry LP boosted its stake in InMode by 154.3% during the third quarter. Quarry LP now owns 3,781 shares of the healthcare company's stock worth $64,000 after buying an additional 2,294 shares during the period. National Bank of Canada FI boosted its position in shares of InMode by 6.2% during the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company's stock worth $169,000 after purchasing an additional 579 shares during the period. GW Henssler & Associates Ltd. acquired a new position in InMode during the third quarter worth $177,000. Finally, DGS Capital Management LLC purchased a new stake in InMode during the third quarter worth about $182,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Down 0.8 %

Shares of INMD traded down $0.14 during trading on Thursday, reaching $17.27. The company's stock had a trading volume of 643,248 shares, compared to its average volume of 835,505. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 9.34 and a beta of 2.12. The company has a fifty day moving average of $17.60 and a two-hundred day moving average of $17.23. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. BTIG Research assumed coverage on InMode in a research report on Thursday, October 17th. They issued a "buy" rating and a $25.00 price target on the stock. Barclays reduced their price objective on shares of InMode from $27.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 9th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research note on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $22.40.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.